�Inverness Medical
Innovations, Inc. (Amex: IMA), a leading provider of near-patient
nosology, monitoring and health direction solutions, is featuring its
new TB diagnostic test, the Clearview TB ELISA, at the International AIDS
conference (AIDS 2008).
The test, which was introduced to development world markets in July
2008, provides a a lot needed attention in the diagnosis of Mycobacterium
tB (TB) in TB/HIV co-infected patients. By providing dependable
information more quickly, when compared to other methods, the Clearview TB
ELISA can enable treatment decisions to be made the very same day, allowing
for more effective patient health management and mitigating the risk of
farther transmission to a extremely vulnerable population.
The Clearview TB ELISA has shown strong carrying out in sleuthing TB in
those co-infected with HIV. Clearview TB ELISA uses antibodies specific to
the antigen lipoarabinomannan (LAM). Elevated levels of the LAM antigen
within the piss of TB/HIV co-infected patients provides a specific and
reliable diagnostic target. Clinical data shows that, piece microscopy
methods detect TB in these TB/HIV co-infected patients, at rates as low as
20%, targeting the LAM antigen victimization the Clearview TB ELISA can give rise
detection rates of 80%.
Ron Zwanziger, Inverness' CEO stated, "Introduction of the Clearview TB
ELISA is an important first tone in making available much-needed diagnostic
tools to address the TB epidemic where the need is superlative. We are working
hard to build support for its widespread adoption."
There were more or less 33 meg people living with HIV infection in
2007 and due to their compromised immune position, more than one third gear were
co-infected with TB. As a result, TB has become a stellar cause of death in
this population and in that respect is a dire need for authentic TB nosology.
By development new capabilities in near-patient diagnosis, monitoring
and wellness management, Inverness Medical Innovations enables individuals to
accept charge of improving their health and quality of life. A global leader
in speedy point-of-care diagnostics, Inverness' products, as well as its new
cartesian product development efforts, focus on infectious disease, cardiology,
oncology, drugs of abuse and women's health. Inverness is headquartered in
Waltham, Massachusetts.
For more information about Inverness Medical Innovations, please visit
our website at http://www.invernessmedical.com.
This press release may contain advanced statements within the
substance of the federal securities laws, including statements regarding
timing of the product release and benefits of the new product. These
statements mull over Inverness' stream views with respect to future events
and are based on its management's current assumptions and entropy
currently available. Actual results may dissent materially due to numerous
factors including, without limitation, risks associated with market place
acceptance of the product; Inverness' power to successfully manufacture
and distribute the product; Inverness ability to secure and maintain the
regulatory approvals or clearances necessary to sell the product in various
markets; and the risks and uncertainties described in Inverness' annual
report card on Form 10-K, and other factors identified from time to time in its
periodical filings with the Securities and Exchange Commission. Inverness
undertakes no obligation to update any forward-looking statements contained
herein.
Inverness Medical Innovations, Inc.
http://www.invernessmedical.com
More info
